In the past month pharmaceutical companies have spent almost $100bn acquiring biotech companies. The FT's Sarah Neville explains why big pharma is raising its bet on the drug pipelines owned by biotechs, and why analysts expect more consolidation in 2019. 

Read more from Sarah at

A transcript for this podcast is currently unavailable, view our accessibility guide.

Get alerts on Behind the Money when a new story is published

Copyright The Financial Times Limited 2021. All rights reserved.
Reuse this content (opens in new window)

Comments have not been enabled for this podcast.

Follow the topics in this podcast